Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 6-K, Date: 2015-08-14
Original SEC Filing: Click here

---

Webplus: WX/20150814/6-K/2_EX-99.1/000.htm SEC Original: d47457dex991.htm
The Company’s board of directors, acting upon the unanimous recommendation of the special committee formed by the board of directors (the “Special Committee”), unanimously approved the Merger Agreement and the transactions contemplated by the Merger Agreement, including the Merger, and resolved to recommend that the Company’s shareholders authorize and approve the Merger Agreement and the transactions contemplated by the Merger

---

---

Webplus: WX/20150814/6-K/3_EX-99.2/000.htm SEC Original: d47457dex992.htm
EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among NEW WUXI LIFE SCIENCE LIMITED, WUXI MERGER LIMITED and WUXI PHARMATECH (CAYMAN) INC. Dated as of August 14, 2015 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01 The Merger 2 Section 1.02 Closing; Closing Date 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 2 Section

---

---

Webplus: WX/20150814/6-K/1/000.htm SEC Original: d47457d6k.htm
Form 6-K Description Press release dated August 14, 2015 Agreement and Plan of Merger among WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited and WuXi Merger Limited, Dated August 14, 2015 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3 6-K 1 d47457d6k.htm FORM 6-K

---

Company Information:

Ticker: WX, Company: WuXi PharmaTech (Cayman) Inc., Type: 6-K, Date: 2015-08-14CIK: 0001403132, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
288 FUTE ZHONG ROAD
SHANGHAI 200131